Please enable Javascript
Conferences
Partners
Expert Interviews
Subscribe
Heme Today
Anemia
Deep Vein Thrombosis
Essential Thrombocythemia
Hemophilia
Immune Thrombocytopenic Purpura
Myelodysplastic Syndromes
Myelofibrosis
Myeloproliferative Neoplasms
PNH
Polycythemia Vera
Pulmonary Embolism
Sickle Cell Disease
Thrombocytopenia
Thrombophilia
Thrombosis
Thrombotic Thrombocytopenic Purpura
Venous Thromboembolism
von Willebrand Disease
Nephrology Times
Acute Kidney Injury
ADPKD
Anemia and Kidney Disease
Chronic Kidney Disease
COVID-19 and Kidney Disease
Diabetes and Hypertension
End-Stage Renal Disease
Gout
Hyperkalemia
IgAN
Kidney Transplantation
Metabolic Acidosis
Breast Cancers Today
HER2 Breast Cancer
HR Breast Cancer
Triple-Negative Breast Cancer
Genetics & Breast Cancer
Cardiology
Atherosclerotic Disease
Atrial Fibrillation
Heart Failure
Hypertension
Interventional Cardiology
Lipid Management
Practice Tips With Dr. Lichaa
Preventive Cardiology
Stroke
Oncology
Breast Cancer
Gynecologic Cancer
Head and Neck Cancer
Skin Cancer
Sleep
Urology
More
Diabetes
Ophthalmology
— Demodex Blepharitis
Neurology
Rheumatology
Gastroenterology
Pulmonology
Infectious Diseases
— HIV
Health and Wellness
Lupus
Future of Medicine
Orthopedics
Pharmacology
Career News
Samuel Cytryn, MD
Samuel Cytryn, MD, Memorial Sloan Kettering Cancer Center
Articles by Samuel Cytryn, MD
Breaking Down DESTINY-Gastric04 and MATTERHORN: Key Updates in Gastric Cancer
Samuel Cytryn, MD
Gastric Cancer
|
March 14, 2025
Dr. Cytryn shares insights on the implications of recent data from the DESTINY-Gastric04 and MATTERHORN trials.
View More
Investigating Novel Immunotherapy Combinations for Advanced Gastric and Esophageal Cancers
Samuel Cytryn, MD
Gastric Cancer
|
March 13, 2025
Dr. Cytryn summarizes a trial in progress investigating a novel immunotherapy combination for gastroesophageal adenocarcinoma
View More
Challenges, Prognosis, and Future Directions for Peritoneal Gastric Cancer
Yelena Janjigian, MD
Gastric Cancer
|
March 13, 2025
The panel discusses considerations around treating peritoneal gastric cancer, including the role of HIPEC.
View More
Antibody Drug Conjugates for Gastric and Esophageal Cancers: Expert Insights
Yelena Janjigian, MD
Gastric Cancer
|
March 13, 2025
In part three of their discussion, the panel explores the role of ADCs in treating gastric and esophageal cancers.
View More
The Role of ctDNA, Claudin 18.2, and PD-L1 in Patient-Centered Gastric Cancer Care
Yelena Janjigian, MD
Gastric Cancer
|
March 13, 2025
The panelists discuss the impact of biomarkers on personalized gastric cancer care, including ctDNA, claudin 18.2, and PD-L1.
View More
Advancing Gastric and Esophageal Cancer Treatment With Biomarker-Driven Strategies
Yelena Janjigian, MD
Gastric Cancer
|
March 13, 2025
An expert panel of GI oncologists debates recent advancements in biomarker-driven strategies for GI cancer care.
View More
FDA Approval of Tislelizumab: RATIONALE-305 Findings and Implications for Practice
Samuel Cytryn, MD
Gastric Cancer
|
March 13, 2025
Dr. Cytryn reviews the FDA approval of tislelizumab and shares thoughts on its clinical impact.
View More
Impact of Zolbetuximab on Gastric Cancer Treatment
Samuel Cytryn, MD
Gastric Cancer
|
March 13, 2025
Dr. Cytryn provides insights on the FDA approval of zolbetuximab and how it will impact clinical practice.
View More